ユタにおける心血管疾患の臨床試験
ユタ内の拠点で、心血管疾患に関する19件の研究が参加者を募集しています。
ユタ内の都市
公式研究テキスト（英語）
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Ogden Clinic - Canyon View, Ogden
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07783802EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Olympus Family Medicine, Salt Lake City
- Velocity Clinical Research-West Jordan-69043, West Jordan
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07064473A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
- Intermountain Medical Center, Murray
被験者募集中第3相
45歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07613294Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Clinical Trial Site, Bountiful
- Clinical Trial Site, Bountiful
- Clinical Trial Site, Layton
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07181109Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
- University of Utah, Salt Lake City
被験者募集中
18歳〜100歳 · 全性別 · 2026/09/09更新 · NCT06310031An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Progressive Clinical Research, Bountiful
- Intermountain Medical Center, Murray
- The University of Utah, Salt Lake City
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/04更新 · NCT07517263Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
- Intermountain, Murray
- VA Salt Lake City Healthcare System, Salt Lake City
被験者募集中第4相健康なボランティア歓迎
75歳以上 · 全性別 · 2026/09/01更新 · NCT04262206A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Bountiful
- Research Site, Ogden
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/24更新 · NCT07000357OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- Alpine Research Organization, Layton
被験者募集中第3相
50歳〜105歳 · 全性別 · 2026/08/21更新 · NCT07136012Global Paradise System US Post Approval Study
- St. Mark's Hospital, Salt Lake City
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/12更新 · NCT06297291Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Intermountain Medical Center, Murray
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/08/07更新 · NCT06813911Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
- Primary Childrens Medical Center, Salt Lake City
被験者募集中第3相
2歳〜11歳 · 全性別 · 2026/07/24更新 · NCT06597006Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
- University of Utah Hospital, Salt Lake City
被験者募集中健康なボランティア歓迎
18歳以上 · 女性 · 2026/06/23更新 · NCT05826925Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
- University of Utah Hospital, Salt Lake City
被験者募集中
18歳以上 · 全性別 · 2026/06/10更新 · NCT06526195Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
- Primary Childrens Medical Center, Salt Lake City
- Primary Childrens Medical Center, Salt Lake City
被験者募集中第3相
6歳〜11歳 · 全性別 · 2026/05/15更新 · NCT06597019Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
- Intermountain Health, Murray
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/04/09更新 · NCT06271577Randomized Trial of SGLT2i in Heart Transplant Recipients
- VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City
被験者募集中第4相
18歳以上 · 全性別 · 2026/01/22更新 · NCT06625073PARTNER 3 Trial - Aortic Valve-in-Valve
- Intermountain Medical Center, Murray
被験者募集中
全年齢 · 全性別 · 2024/05/10更新 · NCT03003299ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。